CN1679864A - Chinese medicine preparation for treating bronchitis - Google Patents
Chinese medicine preparation for treating bronchitis Download PDFInfo
- Publication number
- CN1679864A CN1679864A CN 200510053241 CN200510053241A CN1679864A CN 1679864 A CN1679864 A CN 1679864A CN 200510053241 CN200510053241 CN 200510053241 CN 200510053241 A CN200510053241 A CN 200510053241A CN 1679864 A CN1679864 A CN 1679864A
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- medicine preparation
- semen
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 58
- 239000003814 drug Substances 0.000 title claims description 73
- 206010006451 bronchitis Diseases 0.000 title abstract description 14
- 241001633583 Adenophora Species 0.000 claims abstract description 4
- 241001522129 Pinellia Species 0.000 claims abstract description 4
- 210000000582 semen Anatomy 0.000 claims description 22
- 241000628997 Flos Species 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 4
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 claims description 3
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 3
- 241000218671 Ephedra Species 0.000 claims description 3
- 241000202807 Glycyrrhiza Species 0.000 claims description 3
- 241000207929 Scutellaria Species 0.000 claims description 3
- 206010011224 Cough Diseases 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 20
- 208000006673 asthma Diseases 0.000 abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- 229920001353 Dextrin Polymers 0.000 abstract description 7
- 239000004375 Dextrin Substances 0.000 abstract description 7
- 206010036790 Productive cough Diseases 0.000 abstract description 7
- 235000019425 dextrin Nutrition 0.000 abstract description 7
- 206010012335 Dependence Diseases 0.000 abstract description 5
- 238000002156 mixing Methods 0.000 abstract description 4
- 206010006458 Bronchitis chronic Diseases 0.000 abstract description 3
- 230000001154 acute effect Effects 0.000 abstract description 3
- 208000007451 chronic bronchitis Diseases 0.000 abstract description 3
- 238000001035 drying Methods 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 235000021552 granulated sugar Nutrition 0.000 abstract 2
- 241001465251 Ephedra sinica Species 0.000 abstract 1
- 241000490229 Eucephalus Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 241000801118 Lepidium Species 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 241001448421 Ophiopogon jaburan Species 0.000 abstract 1
- 235000004347 Perilla Nutrition 0.000 abstract 1
- 244000124853 Perilla frutescens Species 0.000 abstract 1
- 244000018633 Prunus armeniaca Species 0.000 abstract 1
- 235000009827 Prunus armeniaca Nutrition 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 240000000377 Tussilago farfara Species 0.000 abstract 1
- 235000004869 Tussilago farfara Nutrition 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 230000037396 body weight Effects 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 206010020880 Hypertrophy Diseases 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 5
- 229920001525 carrageenan Polymers 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 231100000957 no side effect Toxicity 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000000954 anitussive effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 229940124584 antitussives Drugs 0.000 description 3
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal preparation for treating bronchitis, which is prepared from perilla leaf, pinellia tuber, adenophora root, lilyturf root, bitter apricot seed, coltsfoot flower, dried orange peel, baikal skullcap root, mulberry bark, licorice root, smoked plum, Chinese ephedra, lepidium seed and aster root through steps of proportioning, decocting in water, concentrating into extract, adding crushed white granulated sugar and dextrin, fully stirring and mixing the extract with white granulated sugar and dextrin, granulating, drying and subpackaging. The Chinese medicinal preparation for treating cough, expectoration and asthma caused by acute and chronic bronchitis and cough and expectoration caused by cold has the characteristics of quick response, short treatment course and high cure rate, and has no toxic or side effect and no addiction.
Description
Technical field
The present invention relates to the bronchitic Chinese medicine preparation of a kind of treatment, particularly is the Chinese patent medicine of feedstock production with the Chinese herbal medicine.Treat bronchitic Chinese medicine preparation
Background technology
Bronchitis is harm people healthy commonly encountered diseases and frequently-occurring diseases, and is many in the Chinese medicine preparation kind of the treatment bronchitis disease of China's development, but the drug research in this field is made slow progress for a long time.As being used for the treatment of " ZHIKE JUHONG JIAONANG " of bronchitis disease at present, it is slower to take effect after the medication, and the course of treatment is long, and therapeutic effect is not ideal enough.And the bronchitic medicine of the treatment that also has, take the back and produce certain toxic and side effects.
Summary of the invention
The object of the present invention is to provide the bronchitic Chinese medicine preparation of a kind of treatment, cough, expectoration for after the cough that causes of treatment acute/chronic bronchitis, expectoration, asthma and the flu have instant effect, short treating period, the characteristics that cure rate is high, and have no side effect addiction not.
Chinese medicine preparation of the present invention is by making following the composition: (consumption is a weight portion)
Folium Perillae 110-130 Rhizoma Pinelliae 90-110 Radix Adenophorae 13-18 10-14 Radix Ophiopogonis
Semen Armeniacae Amarum 13-18 Flos Farfarae 13-18 Pericarpium Citri Reticulatae 10-14 Radix Scutellariae 11-15
Cortex Mori 10-14 Radix Glycyrrhizae 3-8 Fructus Mume 35-55 Herba Ephedrae 5-9
Semen Lepidii (Semen Descurainiae) 10-14 Radix Asteris 10-14.
Formula optimization weight (part) ratio range of preparation Chinese medicine preparation of the present invention is:
Folium Perillae 115-125 Rhizoma Pinelliae 95-105 Radix Adenophorae 14-16 11-13 Radix Ophiopogonis
Semen Armeniacae Amarum 14-17 Flos Farfarae 14-17 Pericarpium Citri Reticulatae 11-13 Radix Scutellariae 12-14
Cortex Mori 11-13 Radix Glycyrrhizae 4-7 Fructus Mume 40-50 Herba Ephedrae 6-8
Semen Lepidii (Semen Descurainiae) 11-13 Radix Asteris 11-13.
Prescription optimum weight (part) proportioning of preparation Chinese medicine preparation of the present invention is:
15 Radix Ophiopogonis 12 of Folium Perillae 120 Rhizoma Pinelliaes 100 Radix Adenophoraes
Semen Armeniacae Amarum 15 Flos Farfaraees 15 Pericarpium Citri Reticulataes 12 Radix Scutellariaes 13
Cortex Mori 12 Radix Glycyrrhizaes 5 Fructus Mumes 45 Herba Ephedraes 7
Semen Lepidii (Semen Descurainiae) 12 Radix Asteriss 12.
The production method that above-mentioned each component is made Chinese medicine preparation of the present invention is:
With above-mentioned each component 14 the flavor Chinese medicines respectively by the prescription weighing accurate, complete after, the water decocting and concentrating, extract extractum, add white sugar, dextrin after the pulverizing in extractum, the fineness of pulverizing is the 100-120 order, and the weight ratio of extractum, dextrin and white sugar is 2: 0.3: 9.7, extractum and white sugar, dextrin are fully mixed, make granule, oven dry, bag distribution packaging, bronchitic Chinese medicine electuary can obtain medical treatment.
Year meticulously development that is the inventor surplus 30 that the present invention treats bronchitic Chinese medicine preparation through proved recipe, Folium Perillae, Herba Ephedrae in the side have the effect of the cold expelling that induces sweat, depressed lung-energy dispersing; The Rhizoma Pinelliae, Pericarpium Citri Reticulatae, Radix Scutellariae, Radix Glycyrrhizae have drying dampness to eliminate phlegm, regulating qi-flowing for strengthening spleen, the effect of heat-clearing and toxic substances removing; Has Radix Adenophorae (Radix Glehniae), Radix Ophiopogonis the effect of nourishing YIN and clearing away lung-heat, reinforcing stomach reg fluid; Flos Farfarae, Cortex Mori, Semen Lepidii (Semen Descurainiae), Radix Asteris have the effect of nourishing the lung to keep the adverse QI downward, relieving cough and resolving phlegm; The effect that Fructus Mume has astringing the lung, promotes the production of body fluid.Integral formula is considered giving consideration to both the incidental and fundamental, to reach the bronchitic purpose of treatment, is used for the treatment of the diseases such as cough, acute/chronic bronchitis outbreak after bronchitis, the flu.In addition, in the prescription of Chinese medicine preparation of the present invention, there are not toxicity and drugs of addiction.
Chinese medicine preparation clinical practice result of the present invention shows, has instant effect, short treating period, cure rate height, has no side effect, the advantage of addiction not.
For further confirming the advantage that above-described Chinese medicine preparation of the present invention has no side effect to provide following result of the test:
Results of pharmacodynamic test:
One, antitussive and antiasthmatic test
1, antitussive test
Get 50 of mices, male and female have concurrently, and body weight 20 ± 2 grams are according to body weight size random packet 1) the NS group; 2) ZHIKE JUHONG JIAONANG group; 3) Chinese medicine preparation small dose group of the present invention: 4) dosage group in the Chinese medicine preparation of the present invention; 5) the heavy dose of group of Chinese medicine preparation of the present invention; Gastric infusion is 7 days continuously.Half an hour after the last administration, place mice in one glass bell jar, slowly sprays into 1.0ml28% ammonia liquid, observes the incubation period and the cough number of times of mouse cough in two minutes.The results are shown in Table 1.
The influence of table 1 pair antitussive test
| Grouping | Dosage | Incubation period | The cough number of times |
| ??NS | 50ml/kg | ?26.7±9.30 | ??62.5±8.61 |
| ZHIKE JUHONG JIAONANG | 1.2g/kg | ?35.7±7.71** | ??46.7±12.97*** |
| Chinese medicine preparation small dose group of the present invention | 6.5g/kg | ?35.7±11.43* | ??40.8±6.03*** |
| Dosage group in the Chinese medicine preparation of the present invention | 19.5g/kg | ?35.0±12.77* | ??38.7±11.97*** |
| The heavy dose of group of Chinese medicine preparation of the present invention | 30g/kg | ?37.4±12.91** | ??30.3±9.38*** |
* all compare with the NS group P＞0.05 * * P＜0.05 * * * P＜0.01
The result shows: Chinese medicine preparation of the present invention all has in various degree influence to the mouse cough number of times that caused by ammonia and cough latent period, shows as and reduces the cough number of times and prolong cough latent period.
2, expectorant test
Get 50 of mices, male and female have concurrently, and body weight 20 ± 2 grams are divided equally 5 groups at random according to the body weight size, it is the same to divide into groups, gastric infusion is 9 days continuously, and 20 minutes lumbar injection 5% phenol red normal saline solutions were put to death mice after 20 minutes after the last administration, every mice is got bronchus 0.0030 gram, place in the 1ml normal saline, add 1ml/lNaOH0.1ml, measure the trap value in the 546nm place.The results are shown in Table 2.
Table 2 pair mice expectorant test influence X ± SD n=10
| Grouping | Dosage (g/kg) | Trap value (OD) |
| NS | ????50 | ????0.5886±0.0897 |
| ZHIKE JUHONG JIAONANG | ????1.2 | ????0.7263±0.1405** |
| Chinese medicine preparation small dose group of the present invention | ????6.5 | ????0.8344±0.1601*** |
| Dosage group in the Chinese medicine preparation of the present invention | ????19.5 | ????1.2621±0.1770*** |
| The heavy dose of group of Chinese medicine preparation of the present invention | ????30 | ????1.5557±0.3676*** |
* all compare with the NS group P＞0.05 * * P＜0.05 * * * P＜0.01
The result shows: Chinese medicine preparation of the present invention can make mice trachea phenol row increase, and secretion has facilitation to the mouse breathing road to point out Chinese medicine preparation of the present invention.
3, the test of relievining asthma
Get 24 of Cavia porcelluss, male and female have concurrently, body weight 150-200 gram.Divide equally 4 groups at random according to the body weight size, it is the same to divide into groups.Every group 6, half an hour after the administration Cavia porcellus is put into glass bell jar, the record Cavia porcellus caused the time of breathing heavily in 2 minutes.Treat as processing in 2 minutes as surpassing 2 minutes.The results are shown in Table 3.
What table 3 pair Cavia porcellus was relievingd asthma test influences X ± SD n=6
| Grouping | Dosage (g/kg) | Cause the time of breathing heavily (sec) |
| NS | 10 | ????90.67±24.03 |
| ZHIKE JUHONG JIAONANG | 0.32 | ????118.17±4.49** |
| Chinese medicine preparation small dose group of the present invention | 4 | ????93.00±11.71* |
| The heavy dose of group of Chinese medicine preparation of the present invention | 8 | ????119.67±0.82*** |
* all compare with the NS group P＞0.05 * * P＜0.05 * * * P＜0.01
The result shows: but Chinese medicine preparation prolonged guinea pig of the present invention causes the time of breathing heavily, and heavy dose of group relatively has notable difference with matched group.
Two, antiinflammatory test
1, the influence of the mice foot swelling that causes of on Carrageenan
Get 50 of mices, male and female have concurrently, body weight 18～22 grams.Divide equally 5 groups at random by the body weight size, it is the same to divide into groups.Every group 10, successive administration 6 days, half an hour after the last administration, decimal left and right sides toes key film is injection 1% carrageenin down, measures the left paw swelling of half an hour, 1 hour, 2 hours and 4 hours mice and the results are shown in Table 4.
The mice foot swelling that table 4 on Carrageenan causes influence X ± SD n=10
| Grouping | Dosage | Swelling degree (um) | |||
| ?0.5hr | ????1hr | 2hr | ?4hr | ||
| NS | ??50ml/kg | ?1.02±0.13 | ????1.06±0.14 | 1.12±0.15 | ?1.1±0.15 |
| Positive controls | ??1.2g/kg | ?0.84±0.45* | ????0.8±0.45* | 0.9±0.40* | ?1.0±0.39 |
| Chinese medicine preparation small dose group of the present invention | ??6.5g/kg | ?0.8±0.38 | ????0.78±0.33** | 0.97±0.40* | ?1.18±0.30 |
| Dosage group in the Chinese medicine preparation of the present invention | ??19.5g/kg | ?0.88±0.28* | ????0.78±0.21*** | 0.90±0.29** | ?0.27±0.24 |
| The heavy dose of group of Chinese medicine preparation of the present invention | ??30g/kg | ?0.70±0.16*** | ????0.64±0.16*** | 0.69±0.17*** | ?1.11±0.26 |
* all compare with matched group P＞0.05 * * P＜0.05 * * * P＜0.01
The result shows: Chinese medicine preparation of the present invention has inhibitory action in various degree in 0.5hr, 1hr, the caused mice foot swelling of 2hr carrageenin.
2, xylol causes the influence of ear swelling
Get 50 of mices, male and female have concurrently, and body weight 18～22 grams are divided equally 5 groups at random according to the body weight size, and it is the same to divide into groups.Successive administration 7 days, half an hour after the last administration, mouse right ear is smeared dimethylbenzene 50ul, puts to death mice after 30 minutes, gets the auricle weighing of the mice left and right sides, the results are shown in Table 5.
What table 5 xylol caused ear swelling influences X ± SD n=9
| Grouping | Dosage (g/kg) | Left and right sides weight difference (g) |
| NS | 50 | ????0.0086±0.0025 |
| ZHIKE JUHONG JIAONANG | 1.2 | ????0.0059±0.0018** |
| Chinese medicine preparation small dose group of the present invention | 6.5 | ????0.0070±0.0038* |
| Dosage group in the Chinese medicine preparation of the present invention | 19.5 | ????0.0042±0.0019*** |
| The heavy dose of group of Chinese medicine preparation of the present invention | 30 | ????0.0032±0.0020*** |
* all compare with the NS group P＞0.05 * * P＜0.05 * * * P＜0.01
The result shows: dosage group, heavy dose of group all had effect same during Chinese medicine preparation of the present invention can obviously reduce inflammation and react, and more all there were significant differences with matched group.
Experiment conclusion, its function of this experimental evidence cures mainly, and designs its Pharmacodynamic test of active extract: relieving cough and asthma test and antiinflammatory test.The result shows: Chinese medicine preparation of the present invention all has in various degree influence to the mouse cough number of times that caused by ammonia and cough latent period, shows as and reduces the cough number of times and prolong cough latent period; Mice trachea phenol row is increased, and secretion has facilitation to the mouse breathing road to point out Chinese medicine preparation of the present invention; But prolonged guinea pig causes the time of breathing heavily, and heavy dose of group relatively has notable difference with matched group.Chinese medicine preparation of the present invention has inhibitory action in various degree in 0.5hr, 1hr, the caused mice foot swelling of 2hr carrageenin; The dosage group in the reaction, heavy dose of group of obviously reducing inflammation all has effect same, and more all there were significant differences with matched group.To sum up results suggest Chinese medicine preparation of the present invention have the ventilatory function of improvement and cough-relieving, relieving asthma, reduce phlegm, effect such as antiinflammatory.Can be used for treating the diseases such as cough after bronchitis, the flu clinically.
Three, animal acute toxicity test
1, the preparation of medicinal liquid: get the some grams of Chinese medicine preparation of the present invention be mixed with 69.2% be subjected to reagent liquid.
2, the mensuration of oral administration maximum tolerated dose (MDA): get 40 of body weight 20 ± 2 gram mices, male and female half and half, by the continuous gastric infusion 2 times of 0.4ml/10g (being equivalent to crude drug amount 27.6g/kg), 2 hours (being equivalent to crude drug amount 55.2g/kg), observed 7 days continuously at interval, animal activity is all right as a result, no animal dead.
Conclusion: above experimental result shows, Chinese medicine preparation mouse stomach administration LD50＞55.2g/kg of the present invention.Chinese medicine preparation of the present invention adult consumption is with three times on the one, and each 1 bag calculates, and adult's dosage every day is 0.75g/kg, mouse stomach maximum tolerated dose be equivalent to be grown up 73 times of consumption.Point out Chinese medicine preparation clinical drug safety of the present invention.
Four, long-term toxicity test for animals result: after with Chinese medicine preparation of the present invention 80 rats being carried out in accordance with regulations repeat administration test in 90 days, respectively in different periods, kill rat in batches, get its heart, liver, spleen, lung, kidney making specimen, carry out pathological observation at microscopically.
1, heart: the section result, observation post has heart section demonstration to be normal under the mirror.Myocardial cell does not have hypertrophy, and no degeneration, NIP change.Matter and blood vessel do not see that hypertrophy and inflammation change between cardiac muscle.The myocardial cell kytoplasm is high-visible.
2, liver: all liver sections are normal hepatic tissue.Sections observation: see the lobules of liver normal presence under the mirror, hepatic cords is arranged in order, and hepatocyte does not have swelling, distortion, hypertrophy and inflammation and changes.Sinus hepaticus inner cell form and number are normal, do not see hypertrophy and regression.The accidental mild inflammation reaction in portal area.
3, spleen: microscopically sees that all sections of spleen are normal spleen tissue, and splenic white pulp and red pulp structure normal presence do not see that hypertrophy and inflammatory change, and mild hyperaemia is in normal range.
4, lung: all lung sections of microscopically is all normal, and alveolar is normal open configuration, and trachea and bronchus is normal, does not see in the lung that obvious inflammation and hypertrophy change, and interstitial lung also belongs to normal range.
5, kidney: all kidney segments of microscopically are normal nephridial tissue, and glomerule and renal tubules do not have hypertrophy and inflammatory changes, and does not also see hyperemia, and the messangial cell number is in normal range, and matter is normal between kidney.
Conclusion: two batches totally 80 routine rats with various dose, different time, contrast medication test, pathology section examination does not see that rat has unusual pathological change.
Five, clinical efficacy test: for showing that Chinese medicine preparation of the present invention is to bronchitic therapeutic effect, to be diagnosed as bronchitis patient 76 examples, Han nationality's 41 examples wherein, the Uygur nationality's 25 examples, male's 45 examples, women's 31 examples, the oldest person 72 years old, reckling 4 years old, wherein 55 years old-72 years old patient's 54 examples, 15 years old-54 years old patient's 20 examples had 2 examples in 4 years old-14 years old.Be divided into each 38 example of matched group and test group at random by the above-mentioned age, first age bracket (55-72 year) 27 examples, second age bracket (15-54 year), 10 examples, the 3rd age bracket (4-14 year) 1 example, the equal no significant difference of two groups age-sex.
Therapeutic Method: two groups of patients are on the conventional therapy basis, and treatment is organized first age bracket and taken medicine of the present invention 15g/ time, take after mixing it with water for three times on the one; Second age bracket is taken medicine of the present invention 15g/ time, takes after mixing it with water for three times on the one; The 3rd age bracket is taken medicine of the present invention 7.5-15g/ time, takes after mixing it with water for three times on the one.
Matched group gives ZHIKE JUHONG JIAONANG, takes medicine by the routine dose and the method for individual age bracket.
Curative effect is passed judgment on: cure: cough, expectoration, asthma disappear, and the X-ray sheet shows that lung marking is clear; Take a turn for the better: cough, expectoration, asthma alleviate, and X-ray sheet prompting lung marking is slightly thick; Invalid: cough, expectoration, asthma, X-ray sheet all do not have obvious change.
After the treatment group was taken medicine, first age bracket took effect in 48 hours, and second age bracket took effect in 24 hours, and the 3rd age bracket took effect 5-7 days transference cures in 24 hours.
The treatment group is cured 34 examples, accounts for 90.8%; 3 examples that take a turn for the better account for 8.4%; Invalid 1 example accounts for 0.8%, and total effective rate is 99.2%.
After matched group is taken medicine, first age bracket onset after 72 hours; Second age bracket onset after 48 hours, 14 days-1 month transference cures of the 3rd age bracket.
From above observed result analysis, the oral instant effect of Chinese medicine preparation of the present invention as can be seen, short treating period, the cure rate height has no side effect, not addiction.And the treatment time of matched group, the course of treatment, curative effect all are starkly lower than experimental group.Chinese medicine preparation of the present invention is an electuary, has delicious taste, and volume is little, takes and store advantage easily.
The specific embodiment
Take by weighing raw material (weight portion) by following proportioning:
15 Radix Ophiopogonis 12 of Folium Perillae 120 Rhizoma Pinelliaes 100 Radix Adenophoraes
Semen Armeniacae Amarum 15 Flos Farfaraees 15 Pericarpium Citri Reticulataes 12 Radix Scutellariaes 13
Cortex Mori 12 Radix Glycyrrhizaes 5 Fructus Mumes 45 Herba Ephedraes 7
Semen Lepidii (Semen Descurainiae) 12 Radix Asteriss 12.
The production method that above-mentioned each component is made Chinese medicine preparation of the present invention is:
14 of above-mentioned each component is distinguished the flavor of Chinese medicines respectively by after the prescription weighing accurately, and water decocts, and decoction divides three times, decocted 2 hours for the first time, behind the taking-up medicine juice, add water and carry out decocting the second time, decocted 1 hour, after taking out medicine juice, add three decoctions that water carries out, decocted 1 hour, take out medicine juice, three times medicine juice are incorporated into together, are condensed into extractum, the density of extractum is 1.3g/cm
3, concentrate, be that 100-120 adds in the extractum with an amount of white sugar, dextrin smashing fineness, the weight ratio of extractum, dextrin and white sugar is 2: 0.3: 9.7, after stirring, makes granule, oven dry, bag distribution packaging get final product.
Claims (3)
1, the bronchitic Chinese medicine preparation of a kind of treatment is characterized in that it is the medicament of being made by the following weight proportion raw material:
Folium Perillae 110-130 Rhizoma Pinelliae 90-110 Radix Adenophorae 13-18 10-14 Radix Ophiopogonis
Semen Armeniacae Amarum 13-18 Flos Farfarae 13-18 Pericarpium Citri Reticulatae 10-14 Radix Scutellariae 11-15
Cortex Mori 10-14 Radix Glycyrrhizae 3-8 Fructus Mume 35-55 Herba Ephedrae 5-9
Semen Lepidii (Semen Descurainiae) 10-14 Radix Asteris 10-14.
2, the bronchitic Chinese medicine preparation of treatment according to claim 1 is characterized in that wherein the weight proportion of each raw material is:
Folium Perillae 115-125 Rhizoma Pinelliae 95-105 Radix Adenophorae 14-16 11-13 Radix Ophiopogonis
Semen Armeniacae Amarum 14-17 Flos Farfarae 14-17 Pericarpium Citri Reticulatae 11-13 Radix Scutellariae 12-14
Cortex Mori 11-13 Radix Glycyrrhizae 4-7 Fructus Mume 40-50 Herba Ephedrae 6-8
Semen Lepidii (Semen Descurainiae) 11-13 Radix Asteris 11-13.
3, the bronchitic Chinese medicine preparation of treatment according to claim 1 is characterized in that wherein the weight proportion of each raw material is:
15 Radix Ophiopogonis 12 of Folium Perillae 120 Rhizoma Pinelliaes 100 Radix Adenophoraes
Semen Armeniacae Amarum 15 Flos Farfaraees 15 Pericarpium Citri Reticulataes 12 Radix Scutellariaes 13
Cortex Mori 12 Radix Glycyrrhizaes 5 Fructus Mumes 45 Herba Ephedraes 7
Semen Lepidii (Semen Descurainiae) 12 Radix Asteriss 12.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100532413A CN1318071C (en) | 2004-12-15 | 2005-02-17 | Chinese medicine preparation for treating bronchitis |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200410104203.1 | 2004-12-15 | ||
| CN200410104203 | 2004-12-15 | ||
| CNB2005100532413A CN1318071C (en) | 2004-12-15 | 2005-02-17 | Chinese medicine preparation for treating bronchitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1679864A true CN1679864A (en) | 2005-10-12 |
| CN1318071C CN1318071C (en) | 2007-05-30 |
Family
ID=35066870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100532413A Expired - Fee Related CN1318071C (en) | 2004-12-15 | 2005-02-17 | Chinese medicine preparation for treating bronchitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1318071C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101391024B (en) * | 2008-07-25 | 2011-04-06 | 陈楚挺 | Traditional Chinese medicine product for treating emphysema, tracheitis, asthma and cough |
| CN101204509B (en) * | 2006-12-21 | 2012-02-08 | 杨文龙 | Chinese traditional medicine soft capsule and preparation method thereof |
| CN102526464A (en) * | 2012-01-13 | 2012-07-04 | 肖荣筱 | Lung-moistening and inflammation-eliminating traditional Chinese medicinal soup for treating chronic bronchitis |
| JP2012531447A (en) * | 2009-06-30 | 2012-12-10 | フーベイ イーリン メディシン リサーチ インスティテュート カンパニー リミテッド | Pharmaceutical composition for the treatment of bronchitis and its preparation |
| EP2450047A4 (en) * | 2009-06-30 | 2013-04-17 | Hebei Yiling Medicine Res Inst Co Ltd | PHARMACEUTICAL COMPOSITION FOR TREATING BRONCHITIS CONTAINING EPHEDRAE AND PROCESS FOR PREPARING THE SAME |
| CN105998481A (en) * | 2016-06-20 | 2016-10-12 | 昆明理工大学 | Chinese herbal medicine compound preparation for relieving cough and eliminating phlegm and preparation method thereof |
| CN110585334A (en) * | 2019-09-16 | 2019-12-20 | 陕西理工大学 | Chinese herbal medicine oral tablet capable of preventing and treating various chronic obstructive emphysema and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101314015B (en) * | 2008-07-21 | 2010-11-03 | 王俊芳 | Medicament for treating children's asthma |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1103589A (en) * | 1993-12-09 | 1995-06-14 | 卜荣安 | Plaster for treating respiratory system diseases |
| CN1175440A (en) * | 1997-07-10 | 1998-03-11 | 迟经惠 | Pill for cough, asthma and lung carbuncle |
| CN1380098A (en) * | 2002-05-20 | 2002-11-20 | 张勇飞 | Anti-infection compound preparation and its preparation method |
-
2005
- 2005-02-17 CN CNB2005100532413A patent/CN1318071C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101204509B (en) * | 2006-12-21 | 2012-02-08 | 杨文龙 | Chinese traditional medicine soft capsule and preparation method thereof |
| CN101391024B (en) * | 2008-07-25 | 2011-04-06 | 陈楚挺 | Traditional Chinese medicine product for treating emphysema, tracheitis, asthma and cough |
| JP2012531447A (en) * | 2009-06-30 | 2012-12-10 | フーベイ イーリン メディシン リサーチ インスティテュート カンパニー リミテッド | Pharmaceutical composition for the treatment of bronchitis and its preparation |
| EP2450047A4 (en) * | 2009-06-30 | 2013-04-17 | Hebei Yiling Medicine Res Inst Co Ltd | PHARMACEUTICAL COMPOSITION FOR TREATING BRONCHITIS CONTAINING EPHEDRAE AND PROCESS FOR PREPARING THE SAME |
| EP2450046A4 (en) * | 2009-06-30 | 2013-07-03 | Hebei Yiling Medicine Res Inst Co Ltd | MEDICALLY ACTIVE COMPOSITION FOR THE TREATMENT OF BRONCHITIS AND PREPARATION THEREOF |
| CN102526464A (en) * | 2012-01-13 | 2012-07-04 | 肖荣筱 | Lung-moistening and inflammation-eliminating traditional Chinese medicinal soup for treating chronic bronchitis |
| CN102526464B (en) * | 2012-01-13 | 2013-07-17 | 肖荣筱 | Lung-moistening and inflammation-eliminating traditional Chinese medicinal soup for treating chronic bronchitis |
| CN105998481A (en) * | 2016-06-20 | 2016-10-12 | 昆明理工大学 | Chinese herbal medicine compound preparation for relieving cough and eliminating phlegm and preparation method thereof |
| CN110585334A (en) * | 2019-09-16 | 2019-12-20 | 陕西理工大学 | Chinese herbal medicine oral tablet capable of preventing and treating various chronic obstructive emphysema and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1318071C (en) | 2007-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101028507A (en) | Chinese-medicinal composition for treating asthma | |
| CN101342317A (en) | Medicament composition for treating tuberculosis and preparation method thereof | |
| CN1486740A (en) | Chinese medicine composition for treating cancer | |
| CN1679864A (en) | Chinese medicine preparation for treating bronchitis | |
| CN1695694A (en) | Chinese traditional medicine for treating breast disease and preparing technique | |
| CN1149097C (en) | Chinese patent medicine for curing diabetes | |
| CN1272055C (en) | Chinese materia medica preparation of prolonging life for invigorating the kidney yang and producing method | |
| CN1634548A (en) | Pharmaceutical composition for treating viral hepatitis and preparation method thereof | |
| CN102100849B (en) | Chinese medicine preparation for treating lumbar disc herniation and preparation method thereof | |
| CN102106999B (en) | A kind of compound Chinese medicinal preparation for the treatment of dysphagia after apoplexy and preparation method thereof | |
| CN1073439C (en) | Medicine for treating trachitis and asthma and its preparation | |
| CN1318378A (en) | Heat syndrome treating Chinese medicine | |
| CN101249246B (en) | Proprietary Chinese medicine preparations for curing depression after cerebral infarction | |
| CN101152327A (en) | Traditional Chinese medicine for treating avian infectious bronchitis | |
| CN100528214C (en) | Capsule for treating epilepsia and its preparing method | |
| CN1181880C (en) | Compound macrostem onion preparation for curing chronic obstructive lung disease and its preparing method | |
| CN103989762B (en) | Chinese medicine composition of internal organs relieving cough and resolving phlegm and preparation method thereof is rushed down in a kind of heat clearing away | |
| CN1895619A (en) | Chinese-medicinal composition for preventing and treating liver disease and its preparation | |
| CN102526211B (en) | Composition and preparation process of oral medicine for treating constipation | |
| CN1242770C (en) | Pharmaceutical compositions for treating wind-heat cough and its preparation process | |
| CN104491318A (en) | Traditional Chinese preparation used for treating asthma and preparation method of traditional Chinese preparation | |
| CN103006950A (en) | Traditional Chinese medicine for treating pharyngolaryngitis and preparation process thereof | |
| CN1274353C (en) | Medication for curing children's infantile malnutrition and preparation method | |
| CN102366594A (en) | Traditional Chinese medicine for adjusting menstruation | |
| CN102247551A (en) | Medicament for treating constipation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070530 Termination date: 20110217 |